Core Insights - Garmin has announced partnerships with Brooks, Dexcom, Maurten, Shokz, and Therabody to enhance the Garmin Marathon Series, starting with races in Toledo, Ohio on September 21, 2025 [1][8] Company Contributions - **Brooks**: Provides performance running footwear and apparel, offering participants a branded running shirt and showcasing gear at the expo [3] - **Dexcom**: Offers innovative glucose biosensing technology, including the Dexcom G7 and Stelo, to help runners track glucose levels, with a presence at the expo and finish line festival [4] - **Maurten**: Known for sports nutrition, will supply gels at aid stations to support runners during the event, and will also be present at the expo [5] - **Shokz**: Specializes in open-ear listening technology, will showcase headphones at the expo and provide support at cheer stations during the race [6] - **Therabody**: Focuses on recovery devices to enhance athletic performance, offering exclusive deals and recovery zones throughout the event [7] Event Details - The Garmin Marathon Series will feature events in Toledo, Ohio, and Tucson, Arizona, with four race distances: a full marathon, half marathon, 10K, and 5K, with registration currently open [8]

The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will receive newly issued OSRK shares, along with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. WORIO Shareholders Align with OSRH Upside The company emphasizes that the $10 OSRH share condition ...

BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., ...

Deal Overview - Medtronic plc announced its intent to spin off its Diabetes business into a standalone entity, referred to as the New Diabetes Company, to streamline its portfolio and focus on high-margin growth areas [2][3] - The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) [3] Company Focus Post Spin-Off - Post spin-off, Medtronic will concentrate on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies, which together account for over 90% of its total revenues [3][6] - The company aims to accelerate growth through innovation in areas such as pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation [3] Financial Implications - The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market [4] - Medtronic expects its dividend per share to remain unchanged pre- and post-transaction, with no change to its dividend policy [4] Diabetes Segment Performance - The Diabetes segment contributed approximately $2.5 billion in FY25, about 8% of Medtronic's total revenue of $32.4 billion, but has underperformed with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR [7][6] - The segment's operating margin has declined significantly from 30.9% in FY19 to 15.8% in FY25, indicating challenges in profitability [7] Market Challenges - The Diabetes segment has faced multiple headwinds, including FDA regulatory setbacks and increasing competition from agile players like Dexcom and Abbott [8] - Despite a recent rebound with a growth of ~10.7% YoY in FY25, the improvement is insufficient to offset structural challenges [9] Strategic Goals for New Diabetes Company - The New Diabetes Company will focus on creating a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring, and digital health solutions [3][33] - The separation is expected to unlock value for Medtronic and its shareholders, creating a shareholder base more aligned with the financial profile of the New Diabetes Company [12] Company Overview - Medtronic plc is a global healthcare technology leader, operating in over 150 countries and focusing on improving patient outcomes through innovation in various medical technologies [13][32] - The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, addressing a wide range of health conditions [32]

Company Overview - Glucotrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is currently developing a long-term implantable continuous blood glucose monitoring (CBGM) system [5][6] Leadership Addition - Victoria E. Carr-Brendel, PhD, has been elected to Glucotrack's Board of Directors effective May 22, 2025 [1] - Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, having held leadership roles at various companies including Vicarious Surgical Inc. and Sonova Group [2][3] Technology Development - Glucotrack's CBGM is designed as a long-term implantable system that provides continuous blood glucose monitoring for up to three years [3][6] - The system measures glucose directly from blood, offering real-time readings without the lag time associated with traditional continuous glucose monitoring systems [3] Strategic Importance - Dr. Carr-Brendel expressed her commitment to contributing to Glucotrack's strategic and clinical milestones, emphasizing the potential of the CBGM to address unmet needs for diabetes management [3]